Platelet-rich plasma shows positive effect on androgenetic alopecia
Patients who received a half-head treatment of platelet-rich plasma to treat androgenetic alopecia showed a clinical benefit at 6-month follow-up, according to recent research.
“This clinical research provides support that the application of [platelet-rich plasma] may have a therapeutic effect on [androgenetic alopecia] and can be used as a safe complementary treatment option,” Rubina Alves, MD, from the department of dermatology at the Universitat Internacional de Catalunya in Barcelona, Spain and colleagues wrote in their study. “However, more controlled and well-designed clinical trials should be conducted to confirm the clinical improvement of [androgenetic alopecia] with administration of [platelet-rich plasma].”
Alves and colleagues evaluated 25 patients with androgenetic alopecia who received a half-head treatment of platelet-rich plasma, with placebo on the other half-head. The patients had three three platelet-rich plasma treatments, 1 month apart, and a follow-up visit at 6 months.
There were significant differences in mean terminal hair density (165.8 ± 56.8), hair density (179.9 ± 62.7), anagen hairs (67.6 ± 13.1) and telogen hairs (32.4 ± 13.1) at 6-month follow-up on the platelet-rich plasma–treated side compared with baseline measurements (P < .05), and in hair density compared with the control side (P < .05).
“In support of the data obtained, treatment with [platelet-rich plasma] showed a statistically significantly correlation of the mean total hair density between men, patients aged ≤ 40 years, beginning of hair loss ≥ 25 years, positive family history, and > 10 years of evolution of [androgenetic alopecia], when compared with the placebo,” Alves and colleagues wrote. “This study also found a correlation in the areas treated with [platelet-rich plasma] between anagen hairs (%), and patients aged more than 40 years and beginning of [androgenetic alopecia] ≥ 25 years, at 6 months.” – by Jeff Craven
Disclosure: The researchers report no relevant financial disclosures.